Steminent Biotherapeutics Inc.

NT$187.50As of Sun 8 Nov 2026, 12:00 UTC
TPEx:7729Healthcare
Country Taiwan
PE (Fwd) •••
TSR 3Y CAGR 99.22%
Div yield —
ROE (31.72%)
Biotechnology
Beta (5Y) (0.14)
PE TTM —
TSR TTM 363.17%
Mkt cap NT$15.11B
ROIC (18.07%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
NT$191
2.13%
229.08%
Hold 12|3|11|0|8
4Q25
1Q26
2Q26
3Q26
Earnings per shareNT$
2.54
2.51
2.49
2.64
34.06%
25.84%
16.33%
14.70%
RevenueNT$M
726.8
752.3
753.5
749.5
7.67%
6.86%
6.88%
6.40%
Peers (US$458.8M)
Cap (US$)
PE
465.7M
—
439.6M
29.51x
462.3M
43.75x
Capital
TTM
5Y
10Y
Leveragex
3.150
(0.111)
(0.087)
EBIT/Intx
1.130
1.009
0.950
Own earn%
(48.84)
207.51
239.72
Sh yield%
45.32
23.23
20.25
Owners
Insiders/Inst%
0.93
65.94
Short interest%
4.73
SBC / revenue%
0.36
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
11
Op margin range%
7–11
$1 testx
0.1
Incr. ROIC%
46